NICE has recommended a new treatment option for symptoms of endometriosis that can be taken at home.
The final draft guidance recommends Linzagolix (Yselty), with hormonal add-back therapy for adults of reproductive age who have already tried other medical or surgical treatments for their endometriosis.
Endometriosis affects around 1.5 million women across the UK. It occurs when tissue similar to the womb lining grows in other parts of the body. When this tissue breaks down during the menstrual cycle, it becomes trapped in the pelvis, causing chronic pain and fatigue. These symptoms can make everyday activities difficult and greatly impact quality of life.
Linzagolix works by blocking hormones that contribute to endometriosis symptoms. It is taken as a once-daily tablet along with hormone therapy to manage potential side effects. Clinical trials have shown significant reductions in both everyday pelvic pain and painful periods for women taking Linzagolix with hormone therapy.
Helen Knight, Director of Medicines at NICE, commented:
“We're pleased to recommend linzagolix as a new treatment option for endometriosis. As a once-daily tablet taken at home, it offers a convenient way for people with endometriosis to manage their condition and helps to ease pressure on NHS services.
"Thanks to our streamlined process, we've been able to fast-track our evaluation of this treatment to get it to the people who need it, quickly. Linzagolix is a valuable addition to the options available for this often painful and disruptive condition."
NICE used a faster evaluation process to assess this treatment by comparing its costs with similar treatments and standard care options. The NICE committee found that Linzagolix offers similar benefits at a comparable cost, giving patients more treatment choices. The medicine was approved by the UK regulator (MHRA) on 14 March 2025. The final guidance on Linzagolix is due to be published on 25 June, after which the NHS in England must make the treatment available within 90 days.
Image credit: iStock
